Search

Why drug developers should take a fresh look at long-acting dosage forms.

SCHOTT introduces an online shop with low minimum order quantities to overcome the challenges associated with conventional purchase order procedures.

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Queenie Jang reveals how the ISCT created an interactive virtual conference in under two months.

When it comes to using AI in drug development, companies need to consider how they create and protect their intellectual property.

Kiran Mazumdar-Shaw shares the experiences that have helped shape her career, and the lessons learned along the way.

How is the Indian pharmaceutical industry adapting to meet new demands?

Is continuous manufacturing worth the investment for pharma companies?

How can manufacturers avoid frustrating and inadvertent changes to the solid forms of APIs?

It is essential that drug development incorporates the patient view.